ライフステージ別の女性における薬物動態学的変動の理解
Ilaria Campesi1,2, Giampiero Capobianco3,4, Giuseppe Virdis3,4
1Department of Biomedical Sciences, University of Sassari, Sassari, Italy.
Expert opinion on drug metabolism & toxicology
|December 27, 2025
まとめ
ライフステージ別の成人女性における薬物動態学的変動は、効果的な薬物投与量にとって重要である。これらの違いを理解することは、最適な薬物療法を保証し、臨床研究における女性の健康格差を減らす。
科学分野:
- 薬理学
- 臨床薬学
- 医学における性およびジェンダー
背景:
- 歴史的に、成人女性は臨床試験から除外されており、薬物動態学に関する知識のギャップが生じていた。
- この除外により、多様な女性集団に対する薬物療法とケアが最適化されなかった。
- 女性における吸収、分布、代謝、排泄(ADME)に対処することは、安全で効果的な薬物使用のために不可欠である。
研究 の 目的:
- 様々なライフステージにおける成人女性の薬物動態学的変動をレビューすること。
- 年齢、月経周期、妊娠、授乳、その他の要因が薬物動態に及ぼす影響を強調すること。
- 治療薬における性差とモデリングアプローチの例を含めること。
主な方法:
- 成人女性の薬物動態学的データを要約した文献レビュー。
- 薬物吸収、分布、代謝、排泄に影響を与える要因の分析。
- タンパク質ベースの治療薬と生理学的薬物動態モデリングの例を含めること。
主要な成果:
- 年齢、ホルモン変化、ライフスタイルなどの要因により、女性において著しい薬物動態学的変動が存在する。
- 妊娠、授乳、経口避妊薬の使用は、薬物動態学を著しく変化させる。
- 薬物動態学における性差は明らかであり、治療には合わせたアプローチが必要である。
結論:
- ライフステージやライフスタイルに応じた多様な成人女性を含む臨床試験の緊急の必要性。
- 将来の研究は、年齢、ライフステージ、性別に関連する薬物療法の格差を減らすことに焦点を当てるべきである。
- 薬物動態学および性/ジェンダー医学における専門家主導の研究は、患者ケアを進歩させるために不可欠である。
関連する概念動画
Dosage Regimen: Individualization
146
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
146
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
200
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
200
Pharmacokinetics in Pediatric Patients: Drug Distribution
231
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
231
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
176
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
176
Pharmacodynamics in Geriatric Patients: Effects of Age
172
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
172
Pharmacokinetics in Pediatric Patients: Drug Metabolism
165
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
165


